Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy

Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy

Persistently activated STAT3 is a promising target for a new class of anticancer drug development and cancer therapy, as it is associated with tumor initiation, progression, malignancy, drug resistance, cancer stem cell properties, and recurrence. Here, we discovered 3-(2,4-dichloro-phenoxymethyl)-5...

Full description

Bibliographic Details
Main Authors: Byung-Hak Kim, Haeri Lee, Yeonghun Song, Joon-Suk Park, Changdev G. Gadhe, Jiwon Choi, Chung-Gi Lee, Ae Nim Pae, Sanghee Kim, Sang-Kyu Ye
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Journal of Clinical Medicine
Subjects:
3-(2,4-dichloro-phenoxymethyl)-5-trichloromethyl-[1,2,4]oxadiazole (odz10117)
stat3
sh2 domain
targeted therapy
structure-based computational database screening
cell-based high-throughput screening
Online Access:https://www.mdpi.com/2077-0383/8/11/1847

Internet

https://www.mdpi.com/2077-0383/8/11/1847

Similar Items